Twist Bioscience stock enters earnings week after MRD Express launch

Twist Bioscience launched Twist MRD Express on October 29 for cancer researchers developing personalized molecular residual disease tests, according to Business Wire. The custom panels are manufactured at scale, with turnaround starting within one day.

The product targets a trade-off in MRD research. Tumor-informed testing uses a patient's individual tumor variants and can offer higher sensitivity, but personalization traditionally slows development. Twist said MRD Express is designed to deliver personalized panels on tumor-naive timelines.

Product launch expands research offering

MRD Express panels can contain up to 10,000 probes and include modified bases such as locked nucleic acids, which Twist says can improve sequencing sensitivity. The company also offers bioinformatics panel design support, ecommerce ordering and touchless API ordering.

The launch adds a faster workflow to Twist's existing tools for liquid biopsy and MRD research, including its cell-free DNA library preparation kit and cancer reference standard. The commercial opportunity will depend on customer adoption and the ability to scale orders through the company's high-throughput manufacturing platform.

Results date sets next catalyst

Twist plans to release fiscal 2026 fourth-quarter and full-year results before the market opens on Thursday, November 12, followed by an 8:00 a.m. Eastern Time conference call. The reporting period ended September 30, making the release the next scheduled update on revenue, profitability and demand.

The real-time quote of Twist Bioscience stock traded at 123.78 euros on Lang & Schwarz at 14:00 CET on Thursday, November 5.

The broader US market context is available in the S&P 500 market coverage.

Further updates can be found in more news and analyses on Twist Bioscience stock.